AI Article Synopsis
- High-grade B-cell lymphoma, not otherwise specified (HGBL-NOS) is a rare type of cancer with limited data available, and in this study, researchers analyzed 136 HGBL-NOS patients' clinical and genetic characteristics compared to other lymphoma types.
- The findings revealed that HGBL-NOS patients shared similar clinical features and median overall survival rates with DLBCL/HGBL-DH patients, but had worse outcomes than those with DLBCL.
- Additionally, R-EPOCH treatment contributed to better overall survival compared to the standard R-CHOP regimen, and factors like MYC rearrangement and high International Prognostic Index were identified as negative prognostic indicators for HGBL-NOS patients.
Article Abstract
High-grade B-cell lymphoma, not otherwise specified (HGBL-NOS) is rare and data focused on these neoplasms is lacking. We studied the clinicopathologic and genetic features of 136 HGBL-NOS patients and compared them to patients with DLBCL/HGBL-DH (n = 224, defined by 5th Edition WHO) and DLBCL (n = 217). HGBL-NOS patients had clinical features similar to DLBCL/HGBL-DH patients. MYC rearrangement (MYC-R) was present in 43% of HGBL-NOS. With induction regimen similar to DLBCL/HGBL-DH patients, HGBL-NOS patients had a median overall survival (OS) of 28.9 months, similar to DLBCL/HGBL-DH (p = 0.48) but inferior to DLBCL patients (p = 0.03). R-EPOCH induction was associated with improved OS compared with R-CHOP. MYC-R, history of lymphoma, and high IPI were independent adverse prognostic factors in HGBL-NOS patients. Whole transcriptome profiling performed on a subset of HGBL-NOS cases showed a profile more similar to DLBCL/HGBL-DH than to DLBCL; 53% of HGBL-NOS had a DH-like signature (DH-like-Sig) and were enriched for MYC-R. DH-like-Sig+ HGBL-NOS patients had a poorer OS than DH-like-Sig-negative patients (p = 0.04). In conclusion, HGBL-NOS has clinicopathologic features and a gene expression profile more similar to DLBCL/HGBL-DH than to DLBCL. Cases of HGBL-NOS frequently carry MYC-R and have a DH-like-Sig+. R-EPOCH induction in HGBL-NOS appears associated with improved OS compared with standard R-CHOP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41375-022-01778-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High-grade B-cell lymphomas: Double hit and non-double hit.
Hum Pathol
November 2024
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:
Article Synopsis
- * The World Health Organization's 5th edition (WHO-HAEM5) categorizes HGBL into two types: one with specific genetic rearrangements (DLBCL/HGBL) and the other as not otherwise specified (HGBL-NOS).
- * The International Consensus Classification (ICC) adds a category for HGBL with concurrent genetic rearrangements and discusses diagnostic features, molecular genetics, and potential confusion with B lymphoblastic leukemia/lymphoma.
Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients With Relapsed/Refractory Disease.
Clin Lymphoma Myeloma Leuk
January 2025
Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Electronic address:
Background: Large B cell lymphoma (LBCL) is the most common form of lymphoma. Polatuzumab vedotin (polatuzumab) is an effective therapy for patients diagnosed with LBCL; however, only limited information regarding pathologic features detected by clinical laboratory assays is available to determine which patients are most likely to benefit from polatuzumab based therapies.
Patients And Methods: We collected data from real world patients with relapsed or refractory LBCL whose tumors underwent next generation sequencing and were treated with polatuzumab based therapy at a single large academic cancer center.
High-grade B-cell lymphoma with 11q aberration in the HIV setting: a clinicopathological study of 10 cases and literature review.
Infect Agent Cancer
September 2024
Department of Pathology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Article Synopsis
- - High-grade B-cell lymphoma with 11q aberration (HGBL-11q) is recognized as a unique lymphoma subtype that doesn’t have MYC translocation but shows specific chromosome 11q changes, and its occurrence in people with HIV is not well-defined.
- - In a study of aggressive B-cell lymphomas in HIV patients (totaling 96 cases), 10.4% were found to have the HGBL-11q pattern, particularly in Burkitt lymphoma and diffuse large B-cell lymphoma, with a cohort median age of 35 years, all of whom were male.
- - The HGBL-11q cases displayed distinct histological features, including abnormal cell death and varied expression of
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series.
Blood Adv
October 2024
Department of Medicine, Lifespan Cancer Institute, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI.
Article Synopsis
- There is limited knowledge about the risk of central nervous system (CNS) involvement in high-grade B-cell lymphoma, not otherwise specified (HGBL NOS), prompting a study that assessed baseline CNS involvement, recurrence rates, and management strategies in patients treated from 2016 to 2021.
- In the study of 160 adults, 7% exhibited baseline CNS involvement, which was linked to MYC rearrangement and certain sites of involvement, but did not significantly impact overall survival outcomes compared to those without CNS involvement.
- The risk of CNS recurrence within three years was found to be 11%, with patients showing initial CNS involvement facing a much higher risk (48.5%), while various other factors such as blood involvement and
[Interim efficacy of a multicenter cohort study for China Net Childhood Lymphoma mature B-cell lymphoma 2017 regimen in the treatment of pediatric High-grade-B cell lymphoma].
Zhonghua Yi Xue Za Zhi
July 2024
Department of Pediatric Lymphoma, Beijing GoBroad Boren Hospital, Beijing 100070, China.
Article Synopsis
- The study analyzes the effectiveness of a specific chemotherapy regimen (CNCL-B-NHL-2017) for treating children with high-grade B-cell lymphoma (HGBL) from 2017 to 2021 at 16 hospitals in China.
- Researchers categorized patients into two groups based on WHO classification—high-grade B-cell lymphoma with double/triple hits (HGBL-DH/TH) and non-specified (HGBL-NOS)—and conducted a follow-up to December 2023.
- The findings highlighted clinical characteristics, treatment responses, and survival rates, noting that out of 62 patients, most had HGBL-NOS, and different chemotherapy regimens were applied based on the patients' risk categories.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!